Eton Pharma Files Routine 8-K; No Major News Reported
Ticker: ETON · Form: 8-K · Filed: Feb 2, 2024 · CIK: 1710340
Complexity: simple
Sentiment: neutral
Topics: routine-filing, corporate-governance
TL;DR
**Eton Pharma's 8-K is a non-event, nothing major to see here.**
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on February 2, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates standard, routine disclosures without specific details of a major event. For investors, this means there's no immediate news of significant financial changes, acquisitions, or other material events that would typically impact the stock price, suggesting a period of operational normalcy.
Why It Matters
This filing is a standard disclosure, indicating no immediate, significant corporate events that would dramatically alter Eton Pharmaceuticals' financial outlook or stock valuation.
Risk Assessment
Risk Level: low — The filing is routine and does not disclose any new risks or significant changes to the company's operations or financial standing.
Analyst Insight
A smart investor would note this as a non-event and continue to monitor for more substantive filings like 10-Qs or 10-Ks for actual financial performance and strategic updates, as this 8-K provides no new actionable information.
Key Numbers
- 20240202 — Filing Date (Date the 8-K was filed with the SEC)
- 001-38738 — Commission File Number (Unique identifier for Eton Pharmaceuticals with the SEC)
- 16 — Public Document Count (Number of documents associated with this filing)
- $0.001 — Par Value per Share (Par value of Eton Pharmaceuticals' Common Stock)
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- NASDAQ Global Market (company) — the exchange where Eton Pharmaceuticals' common stock is registered
- Delaware (company) — state of incorporation for Eton Pharmaceuticals, Inc.
- 001-38738 (dollar_amount) — Commission File Number for Eton Pharmaceuticals, Inc.
- 37-1858472 (dollar_amount) — I.R.S. Employer Identification Number for Eton Pharmaceuticals, Inc.
Forward-Looking Statements
- Eton Pharmaceuticals will continue to file routine disclosures without major event announcements in the near term. (Eton Pharmaceuticals, Inc.) — medium confidence, target: 2024-05-01
FAQ
What is the purpose of this 8-K filing by Eton Pharmaceuticals, Inc.?
This 8-K filing by Eton Pharmaceuticals, Inc. on February 2, 2024, is categorized under 'Other Events' and 'Financial Statements and Exhibits,' indicating a routine disclosure without specifying a single major event.
When was the earliest event reported in this 8-K filing?
The 'Date of Report (Date of earliest event reported)' for this 8-K filing is February 2, 2024.
Where is Eton Pharmaceuticals, Inc. incorporated and what is its business address?
Eton Pharmaceuticals, Inc. is incorporated in Delaware, and its business address is 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
What is the trading symbol and exchange for Eton Pharmaceuticals, Inc. common stock?
The trading symbol for Eton Pharmaceuticals, Inc. common stock is ETON, and it is registered on the NASDAQ Global Market.
Does this 8-K indicate that Eton Pharmaceuticals, Inc. is an emerging growth company?
The filing includes a checkbox section for 'emerging growth company' but does not indicate that the box is checked, implying it is not being filed under that provision or is not an emerging growth company as defined.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-02-02 06:55:44
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20240119_8k.htm (8-K) — 25KB
- ex_617023.htm (EX-99.1) — 22KB
- 0001437749-24-002872.txt ( ) — 181KB
- eton-20240202.xsd (EX-101.SCH) — 3KB
- eton-20240202_def.xml (EX-101.DEF) — 11KB
- eton-20240202_lab.xml (EX-101.LAB) — 15KB
- eton-20240202_pre.xml (EX-101.PRE) — 11KB
- eton20240119_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On February 2, 2024, Eton Pharmaceuticals, Inc. issued a press release announcing the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit 99.1 Press Release dated February 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 2, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 3